International Business Machines Corporation
IBM · NYSE
IBM · NYSE
IBM sells enterprise technology and services, including software and hybrid-cloud and AI platforms that support business modernization. Its software business is identified in the supplied research as the leader in its core business; the evidence does not provide revenue contributions for individual segments. Customers include enterprise organizations, and IBM also serves the USTA as the US Open’s official AI and cloud partner. The company reports FY2025 revenue of $67.5 billion and net income of $10.6 billion, up from $62.8 billion and $6.0 billion, respectively, in FY2024.
IBM gained 2.45% over the reported period, from $252.11 to $258.28. The daily closes show a two-step dip early in the week: the stock edged down from $253.44 on Monday, October 26, to $250.25 on Tuesday, then recovered to $253.22 Wednesday and rose to $258.28 Thursday. The main company-specific news was Wednesday’s announcement that IBM and the USTA extended their partnership for five years, keeping IBM as the US Open’s official AI and cloud partner through 2031; the evidence does not establish that this drove the subsequent advance. No dated guidance or other clearly attributable trading catalyst explains Thursday’s rise, and the supplied evidence includes no market benchmark for comparison.
IBM rose 4.13%, from $227.02 to $236.39, over the period. It advanced to $230.78 on Tuesday, fell back to $227.88 on Wednesday, jumped to $234.12 on Thursday, eased on Friday, then reached the period high on Monday. The strongest company-specific support was the Q3 report: IBM beat earnings expectations, reported accelerating growth across all three business lines, and guided to full-year revenue growth. The reaction was not uniformly positive: reports said the shares initially struggled despite the earnings beat, amid investor concern about the returns on AI spending. Subsequent target increases from BMO and Truist, citing software outlook and growth, accompanied the rebound. The supplied evidence does not identify a broader market driver.
IBM gained 2.46% over the week, rising from $221.58 to $227.02. Shares slipped for three sessions, reaching $220.51 on Wednesday, then jumped 2.77% on Thursday on the week’s highest volume before edging higher Friday and dipping slightly on Monday. Coverage highlighted Morgan Stanley’s 25% price-target increase, although the firm retained an Equal Weight rating; the available evidence does not establish that the target change caused Thursday’s rally. The move therefore included a sharp midweek reversal, but the supplied information identifies no company announcement or other catalyst that explains it. IBM’s close on Monday was just below Friday’s $227.13.
IBM finished at $221.29, up $1.30, or 0.59%, from $219.99. The largest move in the supplied trading series came on Oct. 1, when the shares rose to $225.62 on volume of 8.9 million, then surrendered most of that gain: they closed at $222.64 on Oct. 2 and eased to $221.29 by Oct. 6. Headlines during the period covered IBM’s SAP integration offering for midsize businesses and its selection by DARPA for quantum-computing work, but the supplied evidence does not establish either as a driver of the share-price moves. Nor does it provide a market benchmark or broader market news to explain the modest net gain.
IBM fell 0.63%, from the supplied $227.06 reference close to $225.62 on October 1. The stock dropped to $220.67 on Monday, then slipped further to $219.93 by Wednesday before rebounding 2.6% on Thursday. Zacks reported the October 1 close was up 2.56% from the prior session, matching that late-week recovery. The supplied coverage does not identify a company-specific announcement that explains the selloff or rebound. Broader market coverage pointed to pressure from rising bond yields, inflation concerns and higher crude prices, alongside a market rebound tied to falling yields and Micron’s strong forecast. IBM’s late-week bounce therefore came after several sessions of declines, but it did not erase the loss against the supplied reference close.
The supplied weekly endpoints show IBM down 1.99%, from $237.49 to $232.76. The daily closes indicate that most of the decline occurred on September 18, when the stock fell to $229.55 on 13.4 million shares, then recovered modestly over September 21–23 to $232.76. That means the stock rose slightly during the stated week beginning September 21, despite the negative move across the supplied endpoints. Company-related headlines included IBM’s z17 in an AI classroom and its Swift digital-asset integration, including a 17-bank pilot; other coverage questioned whether expected growth is reflected in IBM’s guidance. The evidence does not establish that these stories drove the price move, and no market-performance figures are supplied to explain the decline.
IBM fell $1.78, or 0.76%, over the week, from $233.87 to $232.09. Trading was uneven: the stock dropped to $231.40 on September 1, stabilized on September 2, then recovered to $234.71 on September 3 and $234.89 on September 4 before giving back the entire rebound in the final session. The September 8 decline of $2.80 was the largest daily move in the supplied week. The evidence does not identify a company-specific announcement, earnings release, guidance change, or attributable analyst action during this period. Several supplied articles discuss IBM’s AI, quantum, Red Hat, and transaction-processing themes, but their publication dates and direct influence on this week’s trading are not established. Market-wide context is also not provided.
IBM fell 1.71%, from $238.79 to $234.71, with the decline concentrated early in the week before a late recovery. Shares dropped to $233.87 on Monday and $231.40 on Tuesday, then stabilized at $231.70 Wednesday and rebounded 1.30% Thursday. No company-specific announcement in the supplied evidence explains the move. Instead, trading occurred against broader concerns about AI pressure on IBM’s legacy services, cautious estimates, and an ETF outflow alert that specifically included IBM. The stock’s Thursday recovery followed coverage noting IBM had beaten the broader market’s upswing, but it did not reverse the earlier losses.
IBM fell $0.09, or 0.04%, over the week, from $235.68 to $235.59, despite substantial volatility. The stock dropped 1.97% Monday, recovered 1.36% Tuesday, fell another 1.84% Wednesday, surged 3.88% Thursday, and gave back 1.34% Friday. The largest identifiable driver was Thursday’s broad technology rally after Nvidia earnings, when the Nasdaq 100 rose 1.43%; IBM’s gain occurred alongside that market move rather than after a disclosed IBM earnings or guidance event. IBM-specific coverage focused on its dual-architecture Arm mainframe processor and quantum-computing milestone, but the supplied evidence does not establish that either directly drove trading. Options activity and ETF outflow coverage provided no clear directional catalyst.
IBM rose 4.42%, from $226.31 to $236.31, with most of the advance concentrated in Tuesday’s 3.9% jump to $235.15. The move followed coverage of IBM’s enterprise-AI relationship with OpenAI, although several reports noted the stock could still fall despite the partnership, indicating that enthusiasm was not uniform. Attention later shifted to IBM’s $240 million Together AI agreement to build an Nvidia-powered neocloud cluster, reinforcing the company’s AI-infrastructure narrative. Shares added modestly on Wednesday, gave back 1.1% Thursday, then rebounded 1.6% Friday before easing 0.4% on August 10. No earnings or guidance event was supplied; the week’s identifiable catalysts were AI partnerships and infrastructure expansion.
IBM rose 3.34% over the week, from $227.55 to $235.15. The shares initially weakened, falling from $227.55 on July 28 to $221.74 on July 30, before recovering to $223.65 on July 31 and then rallying sharply on August 3-4. The main catalyst was the post-second-quarter earnings reaction: investors looked past a top-line revenue miss and focused on AI momentum and margin expansion. Coverage also highlighted hybrid-cloud demand, Red Hat momentum, and IBM’s AI consulting backlog, while the sovereign-AI partnership with India’s Sarvam provided an additional growth narrative. No evidence indicates a material company-specific reversal after Tuesday’s rally; the week ended at its high.
